<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TIVORBEX- indomethacin capsule </strong><br>Iroko Pharmaceuticals, LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use TIVORBEX™ safely and effectively. See full prescribing information for TIVORBEX.<br><br>TIVORBEX (indomethacin) Capsules for oral use<br>Initial U.S. Approval: 1965</div>
<div class="Warning">
<div>
<h1 class="Warning">WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS</h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold"><span class="Underline">Cardiovascular Risk </span></span> </p>
<ul class="Disc">
<li><span class="Bold">Nonsteroidal anti-inflammatory drugs (NSAIDs) may cause an increased risk of serious cardiovascular thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">TIVORBEX is contraindicated for the treatment of perioperative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery. (<a href="#S4">4</a>)</span></li>
</ul>
<p class="Highlighta"><span class="Bold"><span class="Underline">Gastrointestinal Risk</span></span> </p>
<ul class="Disc"><li><span class="Bold">NSAIDs cause an increased risk of serious gastrointestinal adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (<a href="#S5.2">5.2</a>) </span></li></ul>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div class="Warning">
<div>
<h1 class="Warning">WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS</h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold"><span class="Underline">Cardiovascular Risk </span></span> </p>
<ul class="Disc">
<li><span class="Bold">Nonsteroidal anti-inflammatory drugs (NSAIDs) may cause an increased risk of serious cardiovascular thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">TIVORBEX is contraindicated for the treatment of perioperative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery. (<a href="#S4">4</a>)</span></li>
</ul>
<p class="Highlighta"><span class="Bold"><span class="Underline">Gastrointestinal Risk</span></span> </p>
<ul class="Disc"><li><span class="Bold">NSAIDs cause an increased risk of serious gastrointestinal adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (<a href="#S5.2">5.2</a>) </span></li></ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">TIVORBEX is a NSAID indicated for treatment of mild to moderate <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> in adults (<a href="#S1">1</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li> The dosage is 20 mg orally three times daily or 40 mg orally two or three times daily. (<a href="#S2.1">2.1</a>) </li>
<li> Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. (<a href="#S2.1">2.1</a>)</li>
</ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Capsules: 20 mg or 40 mg (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to indomethacin or any components of the drug product. (<a href="#S4">4</a>)</li>
<li>History of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or other allergic-type reactions after taking aspirin or other NSAIDs. (<a href="#S4">4</a>)</li>
<li>Perioperative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of CABG surgery. (<a href="#S4">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Serious and potentially fatal cardiovascular (CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> can occur with NSAID treatment. Patients with known CV disease or risk factors for CV disease may be at greater risk. Use the lowest effective dose for the shortest duration possible. (<a href="#S5.1">5.1</a>)</li>
<li>Serious gastrointestinal (GI) adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation, which can be fatal. Prescribe TIVORBEX with caution in patients with a prior history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease or GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Use the lowest effective dose for the shortest duration possible. (<a href="#S5.2">5.2</a>)</li>
<li>Elevation of one or more liver tests and severe hepatic reactions. Measure transaminases (ALT and AST) periodically in patients receiving long-term therapy with TIVORBEX. Discontinue TIVORBEX if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop. (<a href="#S5.3">5.3</a>)</li>
<li>New onset or worsening of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Monitor blood pressure closely during treatment with TIVORBEX. (<a href="#S5.4">5.4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. Prescribe TIVORBEX with caution to patients with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. (<a href="#S5.5">5.5</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">Renal papillary necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span> with long-term use. Use TIVORBEX with caution in patients at greatest risk of <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>, including the elderly, and patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver dysfunction, and those taking diuretics and ACE inhibitors. (<a href="#S5.6">5.6</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> may occur in patients with the aspirin triad or without prior exposure to indomethacin. Seek emergency help in cases where an <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> occurs. (<a href="#S5.7">5.7</a>)</li>
<li>Indomethacin may aggravate <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or other psychiatric disturbances, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, and <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>. Use TIVORBEX, with caution in these patients. Discontinue TIVORBEX if severe CNS adverse reactions develop. (<a href="#S5.8">5.8</a>)</li>
<li>Serious skin adverse events such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, which can be fatal. Discontinue TIVORBEX if <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or other signs of local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> occur. (<a href="#S5.9">5.9</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">Most common adverse reactions in clinical trials (incidence ≥2% in TIVORBEX 20 mg and 40 mg groups) include: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, post procedural <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4002836" conceptname="Postoperative hemorrhage">post procedural hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, post procedural <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4142895" conceptname="Near syncope">presyncope</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (upper), <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4172849" conceptname="Generalized pruritus">pruritus generalized</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flush</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>. (<a href="#S6.1">6.1</a>)<br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Iroko Pharmaceuticals, LLC at 1-877-757-0676 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p></div>
<div></div>
<div><div></div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Co-administration with indomethacin may reduce the effect of antihypertensive agents. Concomitant use in patients with compromised renal function may result in further deterioration of renal function. (<a href="#S7.1">7.1</a>, <a href="#S7.3">7.3</a>)</li>
<li>Concomitant administration of indomethacin and anticoagulants and platelet inhibitors (e.g., aspirin) is not generally recommended because of the potential of increased adverse effects including increased GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. (<a href="#S7.2">7.2</a>, <a href="#S7.11">7.11</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Pregnancy: Based on human data, indomethacin may cause fetal harm. Starting at 30 weeks gestation, TIVORBEX should be avoided as premature closure of the ductus arteriosus in the fetus may occur. (<a href="#S5.10">5.10</a>, <a href="#S8.1">8.1</a>)</li>
<li>Pediatric use: The safety and effectiveness of TIVORBEX in pediatric patients 17 years of age and younger has not been established. (<a href="#S8.4">8.4</a>)</li>
</ul></div>
<div><div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
</div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 2/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Initial Dosing</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Cardiovascular Thrombotic Events</a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Gastrointestinal (GI) Effects – Risk of GI Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Hepatic Effects</a></h2>
<h2><a href="#section-5.4" class="toc">5.4	<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5	<span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6	Renal Effects</a></h2>
<h2><a href="#section-5.7" class="toc">5.7	<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8	Central Nervous System Effects</a></h2>
<h2><a href="#section-5.9" class="toc">5.9	<span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10	Fetal Toxicity</a></h2>
<h2><a href="#section-5.11" class="toc">5.11	Corticosteroid Treatment</a></h2>
<h2><a href="#section-5.12" class="toc">5.12	Masking of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></a></h2>
<h2><a href="#section-5.13" class="toc">5.13	Hematological Effects</a></h2>
<h2><a href="#section-5.14" class="toc">5.14	Use in Patients with Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></h2>
<h2><a href="#section-5.15" class="toc">5.15	Monitoring</a></h2>
<h2><a href="#section-5.16" class="toc">5.16	Ocular Effects</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Adverse Reactions From Spontaneous Reports</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	ACE-inhibitors and Angiotensin II Antagonists</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Aspirin</a></h2>
<h2><a href="#section-7.3" class="toc">7.3	Beta-adrenoceptor Blocking Agents</a></h2>
<h2><a href="#section-7.4" class="toc">7.4	Cyclosporine</a></h2>
<h2><a href="#section-7.5" class="toc">7.5	Diflunisal</a></h2>
<h2><a href="#section-7.6" class="toc">7.6	Digoxin</a></h2>
<h2><a href="#section-7.7" class="toc">7.7	Diuretics</a></h2>
<h2><a href="#section-7.8" class="toc">7.8	Lithium</a></h2>
<h2><a href="#section-7.9" class="toc">7.9	Methotrexate</a></h2>
<h2><a href="#section-7.10" class="toc">7.10	NSAIDs</a></h2>
<h2><a href="#section-7.11" class="toc">7.11	Anticoagulants</a></h2>
<h2><a href="#section-7.12" class="toc">7.12	Probenecid</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1	Cardiovascular Effects</a></h2>
<h2><a href="#section-15.2" class="toc">17.2	Gastrointestinal Effects</a></h2>
<h2><a href="#section-15.3" class="toc">17.3	Adverse <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></a></h2>
<h2><a href="#section-15.4" class="toc">17.4	<span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></a></h2>
<h2><a href="#section-15.5" class="toc">17.5	Hepatotoxicity</a></h2>
<h2><a href="#section-15.6" class="toc">17.6	<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span></a></h2>
<h2><a href="#section-15.7" class="toc">17.7	Fetal Toxicity</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
<p class="First"><span class="Bold Underline">Cardiovascular Risk</span></p>
<ul class="Disc">
<li><span class="Bold">NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. [s<span class="Italics">ee <a href="#S5.1">Warnings and Precautions (5.1)</a></span>]</span></li>
<li><span class="Bold">TIVORBEX is contraindicated for the treatment of perioperative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery. [<span class="Italics">see <a href="#S4">Contraindications (4)</a></span>]</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.2"></a><p></p>
<p class="First"><span class="Bold Underline">Gastrointestinal Risk</span></p>
<ul class="Disc"><li><span class="Bold">NSAIDs cause an increased risk of serious gastrointestinal adverse events including, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal.   These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. [<span class="Italics">see <a href="#S5.2">Warnings and Precautions (5.2)</a></span>]</span></li></ul>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">TIVORBEX is indicated for treatment of mild to moderate <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> in adults.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Initial Dosing</h2>
<p class="First">For treatment of mild to moderate <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span>, the dosage is 20 mg three times daily or 40 mg two or three times daily. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">TIVORBEX (indomethacin) Capsules 20 mg – dark blue body and light blue cap (imprinted IP-201 on the body and 20 mg on the cap in white ink).</p>
<p>TIVORBEX (indomethacin) Capsules 40 mg – dark blue body and blue cap (imprinted IP-202 on the body and 40 mg on the cap in white ink).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">TIVORBEX is contraindicated in patients with the following:</p>
<ul class="Disc">
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> and serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>) to indomethacin or any components of the drug product [<span class="Italics">see <a href="#S5.7">Warnings and Precautions (5.7</a>, <a href="#S5.9">5.9)</a></span>]</li>
<li>A history of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients [<span class="Italics">see <a href="#S5.7">Warnings and Precautions (5.7</a>, <a href="#S5.14">5.14)</a></span>]</li>
<li>Perioperative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1)</a></span>]</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Cardiovascular Thrombotic Events</h2>
<p class="First">Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI), and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. All NSAIDs, both COX-2 selective and nonselective, may have a similar risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimize the potential risk for an adverse CV event in patients treated with an NSAID, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development of such events, even in the absence of previous CV symptoms. Inform patients about the signs and/or symptoms of serious CV events and the steps to take if they occur.</p>
<p>Two large, controlled, clinical trials of a COX-2 selective NSAID for the treatment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the first 10-14 days following CABG surgery found an increased incidence of MI and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> [<span class="Italics">see <a href="#S4">Contraindications (4)</a></span>].</p>
<p>There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID, such as indomethacin, does increase the risk of serious gastrointestinal (GI) events [<span class="Italics">see <a href="#S5.2">Warnings and Precautions (5.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Gastrointestinal (GI) Effects – Risk of GI Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</h2>
<p class="First">NSAIDs, including TIVORBEX, can cause serious gastrointestinal (GI) adverse events including <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients, who develop a serious upper GI adverse event on NSAID therapy, is symptomatic. Upper GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, gross <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3-6 months, and in about 2%-4% of patients treated for one year. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term NSAID therapy is not without risk.</p>
<p>In patients taking indomethacin, <span class="product-label-link" type="condition" conceptid="195002" conceptname="Ulceration of intestine">intestinal ulceration</span> has been associated with stenosis and obstruction. <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span> without obvious <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> formation and perforation of pre-existing sigmoid lesions (<span class="product-label-link" type="condition" conceptid="4150051" conceptname="Diverticulum">diverticulum</span>, carcinoma, etc.) have occurred. Increased <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> in <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> patients or the development of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> and regional <span class="product-label-link" type="condition" conceptid="4203614" conceptname="Ileitis">ileitis</span> have been reported to occur.</p>
<p>Prescribe NSAIDs, including TIVORBEX, with extreme caution in patients with a prior history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease or GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Patients with a prior history of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> and/or GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> who use NSAIDs have a greater than 10-fold increased risk for developing a <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI bleed</span> compared to patients with neither of these risk factors. Other factors that increase the risk for GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids or anticoagulants, smoking, use of alcohol, older age, and poor general health status. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore, special care should be taken in treating this population.</p>
<p>To minimize the potential risk for an adverse GI event in patients treated with an NSAID, use the lowest effective dose for the shortest possible duration. Patients and physicians should remain alert for signs and symptoms of GI ulceration and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during NSAID therapy and promptly initiate additional evaluation and treatment if a serious GI adverse event is suspected. This should include discontinuation of the NSAID until a serious GI adverse event is ruled out. For high risk patients, alternative therapies that do not include NSAIDs should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Hepatic Effects</h2>
<p class="First">Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs, including TIVORBEX. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and fatal fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span> and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, some of them with fatal outcomes have been reported.</p>
<p>A patient with symptoms and/or signs suggesting liver dysfunction, or in whom abnormal liver test values have occurred, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with indomethacin. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, etc.), discontinue TIVORBEX immediately.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">NSAIDs, including TIVORBEX, can lead to new onset or worsening of pre-existing <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, either of which may contribute to the increased incidence of CV events.</p>
<p>Use NSAIDs, including TIVORBEX, with caution in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Monitor blood pressure (BP) closely during the initiation of NSAID treatment and throughout the course of therapy.</p>
<p>Patients taking ACE inhibitors, thiazides or loop diuretics or beta-adrenoceptor blocking agents may have impaired response to these therapies when taking NSAIDs [<span class="Italics">see <a href="#S7.1">Drug Interactions (7.1</a>, <a href="#S7.3">7.3</a>, <a href="#S7.7">7.7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	<span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> have been observed in some patients taking NSAIDs. Use TIVORBEX with caution in patients with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
<p>In a study of patients with severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, indomethacin was associated with significant deterioration of circulatory hemodynamics, presumably due to inhibition of prostaglandin dependent compensatory mechanisms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	Renal Effects</h2>
<p class="First">Use caution when initiating treatment with TIVORBEX in patients with considerable <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>.</p>
<p>Long-term administration of NSAIDs has resulted in <span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">renal papillary necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a nonsteroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate over renal decompensation. Patients at greatest risk of this reaction are those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver dysfunction, those taking diuretics and ACE inhibitors, patients with <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state [<span class="Italics">see <a href="#S7.1">Drug Interactions (7.1</a>, <a href="#S7.7">7.7)</a></span>]<span class="Italics">.</span></p>
<p>Increases in serum potassium concentration, including <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, have been reported with use of indomethacin, even in some patients without <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. In patients with normal renal function, these effects have been attributed to a hyporeninemic-<span class="product-label-link" type="condition" conceptid="4028929" conceptname="Hyperreninemic hypoaldosteronism">hypoaldosteronism</span> state.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.6.1"></a><p></p>
<p class="First"><span class="Bold">Advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span></span></p>
<p>No information is available from controlled clinical studies regarding the use of indomethacin in patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. Therefore, treatment with TIVORBEX is not recommended in patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. If TIVORBEX therapy must be initiated, monitor patient renal function closely.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7	<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span></h2>
<p class="First">As with other NSAIDs, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> may occur in patients without known prior exposure to TIVORBEX. TIVORBEX is contraindicated in patients with the aspirin triad. This symptom complex typically occurs in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients who experience <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> with or without <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">nasal polyps</span>, or who exhibit severe, potentially fatal <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> after taking aspirin or other NSAIDs [<span class="Italics">see <a href="#S4">Contraindications (4)</a></span>].</p>
<p>Seek emergency help in cases where an <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8	Central Nervous System Effects</h2>
<p class="First">TIVORBEX may aggravate <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or other psychiatric disturbances, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, and <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, and should be used with considerable caution in patients with these conditions. Discontinue TIVORBEX if severe CNS adverse reactions develop.</p>
<p>TIVORBEX may cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>; therefore, caution patients about engaging in activities requiring mental alertness and motor coordination, such as driving a car. Indomethacin may also cause <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> which persists despite dosage reduction requires cessation of therapy with TIVORBEX.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9	<span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First">NSAIDs, including TIVORBEX, can cause serious skin adverse reactions such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> (SJS), and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), which can be fatal. These serious events may occur without warning. Patients should be informed about the signs and symptoms of serious skin manifestations, and discontinue the use of TIVORBEX at the first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> [<span class="Italics">see <a href="#S4">Contraindications (4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10	Fetal Toxicity</h2>
<p class="First">Starting at 30 weeks gestation, TIVORBEX and other NSAIDs should be avoided by pregnant women as premature closure of the ductus arteriosus in the fetus may occur. If this drug is used during this time period in pregnancy, the patient should be apprised of the potential hazard to a fetus [<span class="Italics">see <a href="#S8.1">Use in Specific Populations (8.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11	Corticosteroid Treatment</h2>
<p class="First">TIVORBEX cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to exacerbation of corticosteroid-responsive illness. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.12"></a><a name="section-5.12"></a><p></p>
<h2>5.12	Masking of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></h2>
<p class="First">The pharmacological activity of TIVORBEX in reducing <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, and possibly <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, may diminish the utility of diagnostic signs in detecting infectious complications of presumed noninfectious, painful conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.13"></a><a name="section-5.13"></a><p></p>
<h2>5.13	Hematological Effects</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> may occur in patients receiving NSAIDs, including TIVORBEX. This may be due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. In patients receiving long-term therapy with NSAIDs, including TIVORBEX, check hemoglobin or hematocrit if they exhibit any signs or symptoms of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> or blood loss. TIVORBEX is not indicated for long-term treatment.</p>
<p>NSAIDs inhibit platelet aggregation and have been shown to prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Carefully monitor patients treated with TIVORBEX who may be adversely affected by alterations in platelet function, such as those with <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorders</span> or patients receiving anticoagulants.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.14"></a><a name="section-5.14"></a><p></p>
<h2>5.14	Use in Patients with Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> may have aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. The use of aspirin in patients with aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has been associated with severe <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> which can be fatal. Since cross reactivity, including <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, TIVORBEX is contraindicated in patients with this form of aspirin sensitivity and should be used with caution in all patients with preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> [<span class="Italics">see <a href="#S4">Contraindications (4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.15"></a><a name="section-5.15"></a><p></p>
<h2>5.15	Monitoring</h2>
<p class="First">Because serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, physicians should monitor for signs or symptoms of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. For patients on long-term treatment with NSAIDs, periodically check their CBC and chemistry profile including liver function tests. Discontinue TIVORBEX if clinical signs and symptoms consistent with liver or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> develop, systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, etc.) or if abnormal liver tests persist or worsen. TIVORBEX is not indicated for long-term treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.16"></a><a name="section-5.16"></a><p></p>
<h2>5.16	Ocular Effects</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4080669" conceptname="Keratic precipitates">Corneal deposits</span> and retinal disturbances, including those of the macula, have been observed in some patients who had received prolonged therapy with TIVORBEX. Be alert to the possible association between the changes noted and TIVORBEX. It is advisable to discontinue therapy if such changes are observed. <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span> may be a significant symptom and warrants a thorough ophthalmological examination. Since these changes may be asymptomatic, ophthalmologic examination at periodic intervals is desirable in patients receiving prolonged therapy. TIVORBEX is not indicated for long-term treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed elsewhere in the labeling:</p>
<ul class="Disc">
<li>Cardiovascular thrombotic events [<span class="Italics">see <a href="#BOX">Boxed Warning</a>  and <a href="#S5.1">Warnings and Precautions (5.1)</a></span>]</li>
<li>Gastrointestinal effects [<span class="Italics">see <a href="#BOX">Boxed Warning</a> and <a href="#S5.2">Warnings and Precautions (5.2)</a></span>]</li>
<li>Hepatic effects [<span class="Italics">see <a href="#S5.3">Warnings and Precautions (5.3)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> [<span class="Italics">see <a href="#S5.4">Warnings and Precautions (5.4)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> [<span class="Italics">see <a href="#S5.5">Warnings and Precautions (5.5)</a></span>]</li>
<li>Renal effects [<span class="Italics">see <a href="#S5.6">Warnings and Precautions (5.6)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> [<span class="Italics">see <a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>
</li>
<li>Central nervous system effects [<span class="Italics">see <a href="#S5.8">Warnings and Precautions (5.8)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin reactions</span> [<span class="Italics">see <a href="#S5.9">Warnings and Precautions (5.9)</a></span>]</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>Five hundred and fifty-four patients (554) received TIVORBEX 20 mg or 40 mg for up to 48 hours in two double-blind, placebo-controlled, clinical trials of <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> following bunionectomy. The most frequent adverse reactions in these trials are summarized below.</p>
<a name="table1"></a><table width="100%">
<caption><span>Table 1           Summary  of Adverse Reactions (≥2% in TIVORBEX 20 mg or 40 mg group) -  Phase 3 Studies in Patients With Postsurgical <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></span></caption>
<col align="center" valign="bottom" width="28%">
<col align="center" valign="bottom" width="18%">
<col align="center" valign="bottom" width="18%">
<col align="center" valign="bottom" width="18%">
<col align="center" valign="bottom" width="18%">
<thead>
<tr class="First">
<th align="center" rowspan="3" valign="middle">Any Treatment Emergent AE</th>
<th align="center">TIVORBEX 40 mg three  times daily<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th align="center">TIVORBEX 40 mg twice daily<a href="#footnote-1" class="Sup">*</a>
</th>
<th align="center">TIVORBEX 20 mg three  times daily<a href="#footnote-1" class="Sup">*</a>
</th>
<th align="center">Placebo<a href="#footnote-1" class="Sup">*</a>
</th>
</tr>
<tr>
<th align="center">(%)</th>
<th align="center">(%)</th>
<th align="center">(%)</th>
<th align="center">(%)</th>
</tr>
<tr class="Last">
<th align="center">N=187</th>
<th align="center">N=184</th>
<th align="center">N=183</th>
<th align="center">N=188</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>One tablet of hydrocodone/acetaminophen 10 mg/325 mg was permitted every 4 to 6 hours as rescue medication for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> management. There was a greater use of concomitant opioid rescue medication in placebo-treated patients than in TIVORBEX-treated patients <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>].</span>
</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="center"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">33</td>
<td align="center">33</td>
<td align="center">34</td>
<td align="center">36</td>
</tr>
<tr>
<td align="center">Post procedural <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></td>
<td align="center">24</td>
<td align="center">22</td>
<td align="center">26</td>
<td align="center">32</td>
</tr>
<tr>
<td align="center"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">16</td>
<td align="center">14</td>
<td align="center">11</td>
<td align="center">11</td>
</tr>
<tr>
<td align="center"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">15</td>
<td align="center">14</td>
<td align="center">10</td>
<td align="center">17</td>
</tr>
<tr>
<td align="center"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center">8</td>
<td align="center">10</td>
<td align="center">12</td>
<td align="center">11</td>
</tr>
<tr>
<td align="center"><span class="product-label-link" type="condition" conceptid="4002836" conceptname="Postoperative hemorrhage">Post procedural hemorrhage</span></td>
<td align="center">5</td>
<td align="center">11</td>
<td align="center">5</td>
<td align="center">6</td>
</tr>
<tr>
<td align="center"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center">4</td>
<td align="center">5</td>
<td align="center">6</td>
<td align="center">5</td>
</tr>
<tr>
<td align="center"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">4</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center">3</td>
<td align="center">2</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center">Post procedural <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center"><span class="product-label-link" type="condition" conceptid="4142895" conceptname="Near syncope">Presyncope</span></td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr>
<td align="center"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center">2</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, upper</td>
<td align="center">2</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center">2</td>
<td align="center">2</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center"><span class="product-label-link" type="condition" conceptid="4172849" conceptname="Generalized pruritus">Pruritus generalized</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">1</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span></td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center"><span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot flush</span></td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr class="Last">
<td align="center"><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Adverse Reactions From Spontaneous Reports</h2>
<p class="First">The following adverse reactions have been identified during post approval use of indomethacin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Bold"><span class="Italics">Gastrointestinal</span>: </span><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span> (includes distension)<span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="4215578" conceptname="Proctitis">proctitis</span><span class="Bold">, </span>single or multiple ulcerations, including perforation and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> of the esophagus, stomach, duodenum or small and large intestines <span class="product-label-link" type="condition" conceptid="195002" conceptname="Ulceration of intestine">intestinal ulceration</span> associated with stenosis and obstruction, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> without obvious <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> formation and perforation of pre-existing sigmoid lesions (<span class="product-label-link" type="condition" conceptid="4150051" conceptname="Diverticulum">diverticulum</span>, carcinoma, etc) development of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> and regional <span class="product-label-link" type="condition" conceptid="4203614" conceptname="Ileitis">ileitis</span> <span class="product-label-link" type="condition" conceptid="4160872" conceptname="Recurrent aphthous ulcer">ulcerative stomatitis</span><span class="Bold">, </span>toxic <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (some fatal cases have been reported)<span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="4044413" conceptname="Stenosis of intestine">intestinal strictures</span> (diaphragms).</p>
<p><span class="Bold Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>.</p>
<p><span class="Bold Italics">Hematologic: </span><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> secondary to obvious or occult <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span>.</p>
<p><span class="Bold Italics">Central Nervous System: </span><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> (includes <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>)<span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="4319906" conceptname="Dyskinesia">involuntary muscle movements</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">psychic disturbances</span> including <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic episodes</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, light-headedness, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, aggravation of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: </span><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">acute anaphylaxis</span><span class="Bold">, </span>acute <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> rapid <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> resembling a <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>-like state<span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.</p>
<p><span class="Bold Italics">Metabolic: </span><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> or <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span></p>
<p><span class="Bold Italics">Genitourinary:</span> <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>: BUN elevation, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
<p><span class="Bold Italics">Special Senses:</span> ocular — <span class="product-label-link" type="condition" conceptid="4080669" conceptname="Keratic precipitates">corneal deposits</span> and retinal disturbances, including those of the macula, have been reported in some patients on prolonged therapy with indomethacin; <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, hearing disturbances, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>.</p>
<p><span class="Bold"><span class="Italics">Skin and Appendages:</span></span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span> or <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span><span class="Bold">, </span>loss of hair<span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>.</p>
<p><span class="Bold"><span class="Italics">Miscellaneous:</span></span> <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span><span class="Bold">, </span>breast changes, including enlargement and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span><span class="Bold">, </span><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.1"></a><p></p>
<p class="First"><span class="Bold">Causal relationship unknown</span></p>
<p>Other reactions have been reported but occurred under circumstances where a causal relationship could not be established. However, in these rarely reported events, the possibility cannot be excluded. Therefore, these observations are being listed to serve as alerting information to physicians:</p>
<p><span class="Bold Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span></p>
<p><span class="Bold"><span class="Italics">Hematologic:</span></span> Although there have been several reports of <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>, the supporting information is weak</p>
<p><span class="Bold"><span class="Italics">Genitourinary:</span></span> <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary frequency</span></p>
<p><span class="Bold"><span class="Italics">Musculoskeletal and Connective Tissue:</span></span> A rare occurrence of fulminant <span class="product-label-link" type="condition" conceptid="133566" conceptname="Necrotizing fasciitis">necrotizing fasciitis</span>, particularly in association with Group Ab hemolytic streptococcus, has been described in persons treated with nonsteroidal anti-inflammatory agents, including indomethacin, sometimes with fatal outcome [<span class="Italics">see <a href="#S5.9">Warnings and Precautions (5.9)</a></span>].</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	ACE-inhibitors and Angiotensin II Antagonists</h2>
<p class="First">NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors and angiotensin II antagonists. Indomethacin can reduce the antihypertensive effects of captopril and losartan. These interactions should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors or angiotensin II antagonists. In some patients with compromised renal function, the co-administration of an NSAID and an ACE-inhibitor or an angiotensin II antagonist may result in further deterioration of renal function, including possible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, which is usually reversible [<span class="Italics">see <a href="#S5.6">Warnings and Precautions (5.6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Aspirin</h2>
<p class="First">When administered with aspirin, indomethacin's protein binding is reduced, although the clearance of free indomethacin is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of indomethacin and aspirin is not generally recommended because of the potential of increased adverse effects.</p>
<p>The use of indomethacin in conjunction with aspirin or other salicylates is not recommended. Controlled clinical studies have shown that the combined use of indomethacin and aspirin does not produce any greater therapeutic effect than the use of indomethacin alone. In a clinical study of the combined use of indomethacin and aspirin, the incidence of gastrointestinal side effects was significantly increased with combined therapy.</p>
<p>In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3	Beta-adrenoceptor Blocking Agents</h2>
<p class="First">Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by NSAIDs including indomethacin has been reported. Therefore, when using these blocking agents to treat <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, patients should be observed carefully in order to confirm that the desired therapeutic effect has been obtained.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4	Cyclosporine</h2>
<p class="First">Administration of NSAIDs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin. Use caution when NSAIDs are administered concomitantly with cyclosporine. Carefully monitor patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.5"></a><a name="section-7.5"></a><p></p>
<h2>7.5	Diflunisal</h2>
<p class="First">In normal volunteers receiving indomethacin, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin. In some patients, combined use of indomethacin and diflunisal has been associated with fatal <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>. Therefore, diflunisal and indomethacin should not be used concomitantly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.6"></a><a name="section-7.6"></a><p></p>
<h2>7.6	Digoxin</h2>
<p class="First">Indomethacin given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. Therefore, when indomethacin and digoxin are used concomitantly, serum digoxin levels should be closely monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.7"></a><a name="section-7.7"></a><p></p>
<h2>7.7	Diuretics</h2>
<p class="First">Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis.</p>
<p>Indomethacin reduces basal plasma renin activity (PRA), as well as those elevations of PRA induced by furosemide administration, or salt or <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>. These facts should be considered when evaluating plasma renin activity in hypertensive patients.</p>
<p>It has been reported that the addition of triamterene to a maintenance schedule of indomethacin resulted in reversible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> in two of four healthy volunteers. Indomethacin and triamterene should not be administered together.</p>
<p>Indomethacin and potassium-sparing diuretics each may be associated with increased serum potassium levels. The potential effects of indomethacin and potassium-sparing diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently.</p>
<p>Most of the above effects concerning diuretics have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by indomethacin.</p>
<p>During concomitant therapy with NSAIDs, observe patients closely for signs of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, as well as to assure diuretic efficacy [<span class="Italics">see <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.8"></a><a name="section-7.8"></a><p></p>
<h2>7.8	Lithium</h2>
<p class="First">NSAIDs, including indomethacin, have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%. These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID. Thus, when NSAIDs and lithium are administered concurrently, observe patients carefully for signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. See the Prescribing Information for lithium preparations before use of such concomitant therapy. In addition, the frequency of monitoring serum lithium concentration should be increased at the outset of such combination drug treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.9"></a><a name="section-7.9"></a><p></p>
<h2>7.9	Methotrexate</h2>
<p class="First">NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that they could enhance the toxicity of methotrexate. Use caution when NSAIDs are administered concomitantly with methotrexate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.10"></a><a name="section-7.10"></a><p></p>
<h2>7.10	NSAIDs</h2>
<p class="First">The concomitant use of indomethacin with other NSAIDs is not recommended due to the increased possibility of <span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">gastrointestinal toxicity</span>, with little or no increase in efficacy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.11"></a><a name="section-7.11"></a><p></p>
<h2>7.11	Anticoagulants</h2>
<p class="First">Caution should be exercised when NSAIDs, such as indomethacin, and anticoagulants are administered concomitantly. The effects of anticoagulants (such as warfarin) and NSAIDs on GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> are synergistic, such that users of both drugs together have a risk of serious GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> higher than that with use of either drug alone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.12"></a><a name="section-7.12"></a><p></p>
<h2>7.12	Probenecid</h2>
<p class="First">When indomethacin is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased. Therefore, a lower total daily dosage of indomethacin may produce a satisfactory therapeutic effect. When increases in the dose of indomethacin are made, they should be made carefully and in small increments.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category C prior to 30 weeks gestation; </span></p>
<p><span class="Bold">Category D starting at 30 weeks gestation.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.1"></a><p></p>
<p class="First"><span class="Italics">Risk Summary</span></p>
<p>There are no adequate and well-controlled studies of TIVORBEX in pregnant women. Starting at 30 weeks gestation, TIVORBEX, and other NSAIDs, should be avoided by pregnant women as premature closure of the ductus arteriosus in the fetus may occur. TIVORBEX can cause fetal harm when administered starting at 30 weeks gestation. If the drug is used during this time period in pregnancy, the patient should be apprised of the potential hazard to the fetus. Prior to 30 weeks gestation, TIVORBEX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In animal reproduction studies, retarded fetal ossification was observed with administration of indomethacin to mice and rats during organogenesis at doses 0.16 and 0.32 times, respectively, the maximum recommended human dose (MRHD, 120 mg).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.2"></a><p></p>
<p class="First"><span class="Italics">Clinical Considerations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.2.1"></a><p></p>
<p class="First"><span class="Underline">Fetal and Neonatal Adverse Reactions</span></p>
<p>The known effects of indomethacin and other NSAIDs on the human fetus during the third trimester of pregnancy include: constriction of the ductus arteriosus, <span class="product-label-link" type="condition" conceptid="4006971" conceptname="Tricuspid valve regurgitation">tricuspid incompetence</span>, and <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>; non-closure of the ductus arteriosus postnatally which may be resistant to medical management; myocardial degenerative changes, platelet dysfunction with resultant <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, renal dysfunction or failure, <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>/dysgenesis which may result in prolonged or permanent <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> or perforation, and increased risk of <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing enterocolitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.2.2"></a><p></p>
<p class="First"><span class="Underline">Labor or Delivery</span></p>
<p>The effects of TIVORBEX on labor and delivery in pregnant women are unknown. In rat studies, maternal exposure to NSAIDs, as with other drugs known to inhibit prostaglandin synthesis, increased the incidence of dystocia, delayed parturition, and decreased pup  survival.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.3"></a><p></p>
<p class="First"><span class="Italics">Data</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.3.1"></a><p></p>
<p class="First"><span class="Underline">Animal data</span></p>
<p>Reproductive studies were conducted in mice and rats at dosages of 0.5, 1.0, 2.0, and 4.0 mg/kg/day. Except for retarded fetal ossification at 4 mg/kg/day (0.16 times [mice] and 0.32 times [rats] the MRHD on a mg/m<span class="Sup">2</span> basis, respectively) considered secondary to the decreased average fetal weights, no increase in <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> was observed as compared with control groups. Other studies in mice reported in the literature using higher doses (5 to 15 mg/kg/day, 0.20 to 0.60 times MRHD on a mg/m<span class="Sup">2 </span>basis) have described maternal toxicity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, increased fetal resorptions, and <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span>. Comparable studies in rodents using high doses of aspirin have shown similar maternal and fetal effects.</p>
<p>Maternal indomethacin administration of 4.0 mg/kg/day during the last 3 days of gestation was associated with an increased incidence of neuronal <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> in the diencephalon in the live-born fetuses however no increase in neuronal <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> was observed at 2.0 mg/kg/day as compared to the control groups. Administration of 0.5 or 4.0 mg/kg/day to offspring during the first 3 days of life did not cause an increase in neuronal <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> at either dose level.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Based on available published data, indomethacin may be present in human milk. In one study, levels of indomethacin in breast milk were below the sensitivity of the assay (&lt;20 mcg/L) in 11 of 15 women using doses ranging from 75 mg orally to 300 mg rectally daily (0.94 to 4.29 mg/kg daily) in the postpartum period. Based on these levels, the average concentration present in breast milk was estimated to be 0.27% of the maternal weight-adjusted dose. In another study indomethacin levels were measured in breast milk of eight postpartum women using doses of 75 mg daily and the results were used to calculate an estimated infant daily dose. The estimated infant dose of indomethacin from breast milk was less than 30 µg/day or 4.5 µg/ kg/day assuming breast milk intake of 150 ml/kg/day. This is 0.5% of the maternal weight-adjusted dosage or about 3% of the neonatal dose for treatment of <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span>. The developmental and health benefits of human milk feeding should be considered along with the mother's clinical need for TIVORBEX and any potential adverse effects on the human milk-fed child from the drug or from the underlying maternal condition. Exercise caution when TIVORBEX is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of TIVORBEX in pediatric patients 17 years of age and younger has not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">As with any NSAIDs, caution should be exercised in treating the elderly (65 years and older) since advancing age appears to increase the possibility of adverse reactions. Elderly patients seem to tolerate ulceration or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> less well than other individuals and many spontaneous reports of fatal GI events are in this population [<span class="Italics">see <a href="#S5.2">Warnings and Precautions (5.2)</a></span>].</p>
<p>Indomethacin may cause <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> or rarely, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> [<span class="Italics">see <a href="#S6.2">Adverse Reactions (6.2)</a>];</span> physicians should remain alert to the possibility of such adverse effects in the elderly.</p>
<p>This drug is known to be substantially excreted by the kidney and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function [<span class="Italics">see <a href="#S5.6">Warnings and Precautions (5.6)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">The following symptoms may be observed following overdosage: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, intense <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, or <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>. There have been reports of <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.</p>
<p>Patients should be managed by symptomatic and supportive care following an NSAID <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. There are no specific antidotes. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> and/or activated charcoal (60 to 100 g in adults, 1 to 2 g/kg in children) and/or osmotic cathartic may be indicated in patients seen within 4 hours of ingestion with symptoms or following a large <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (5 to 10 times the usual dose). Forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, alkalinization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.</p>
<p>For additional information about <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> treatment contact a poison control center (1-800-222-1222).</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">TIVORBEX (indomethacin) Capsules contains the indole derivative NSAID indomethacin. TIVORBEX is available as hard gelatin capsules of 20 mg and 40 mg for oral administration. The chemical name is 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid. The molecular weight is 357.8. Its molecular formula is C<span class="Sub">19</span>H<span class="Sub">16</span>ClNO<span class="Sub">4</span>, and it has the following structural formula.</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=04ca474c-798e-43dd-be7a-1b36720e6a3d&amp;name=tivorbex-01.jpg"></div>
<p>The inactive ingredients in TIVORBEX include: lactose monohydrate, sodium lauryl sulfate, microcrystalline cellulose, croscarmellose sodium and sodium stearyl fumarate. The capsule shells contain gelatin, titanium dioxide, and dyes FD&amp;C blue #1, FD&amp;C blue #2 and FD&amp;C Red #40. The imprinting on the gelatin capsules is white edible ink. The 20 mg capsules have a dark blue body imprinted with IP-201 and light blue cap imprinted with 20 mg in white ink. The 40 mg capsules have a dark blue body imprinted with IP-202 and blue cap imprinted with 40 mg in white ink.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">TIVORBEX is a NSAID with analgesic and antipyretic and analgesic properties.</p>
<p>The mechanism of action of TIVORBEX, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).</p>
<p>Indomethacin is a potent inhibitor of prostaglandin synthesis in vitro. Indomethacin concentrations are reached during therapy which have been demonstrated to produce in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in animal models. Prostaglandins are mediators of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. Since indomethacin is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The relative bioavailability of TIVORBEX 40 mg capsules was compared to indomethacin immediate-release (IR) capsules 50 mg in 38 healthy subjects under fasted conditions in a single-dose crossover study.</p>
<p>TIVORBEX (indomethacin) 40 mg capsules do not result in an equivalent systemic exposure to 50 mg indomethacin IR capsules.</p>
<p>When taken under fasted conditions, a 20% lower dose of indomethacin in TIVORBEX 40 mg capsules resulted in a 21% lower mean systemic exposure (AUC<span class="Sub">inf</span>) and an equivalent mean peak concentration (C<span class="Sub">max</span>) compared to 50 mg indomethacin IR capsules. The median time to reach peak concentrations (T<span class="Sub">max</span>) was 1.67 hours and 2.02 hours for TIVORBEX capsules and Indomethacin IR capsules, respectively.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Bold Italics">Absorption</span></p>
<p>Similar to indomethacin IR capsules, following single oral doses of TIVORBEX capsules 20 mg or 40 mg, indomethacin is readily absorbed. TIVORBEX Capsules attained peak plasma concentrations of approximately 1.2 and 2.4 mcg/mL, respectively, at 1.67 hours. Indomethacin is virtually 100% bioavailable, with 90% of the dose absorbed within 4 hours following dosing.</p>
<p>Administration of TIVORBEX Capsules 20 mg and 40 mg was associated with dose proportional pharmacokinetics.</p>
<p>Taking TIVORBEX with food causes a significant decrease in the rate but not the overall extent of systemic absorption of indomethacin compared to taking TIVORBEX on an empty stomach. TIVORBEX capsules results in 46% lower C<span class="Sub">max</span>, 9% lower AUC<span class="Sub">inf</span>, and 1.33 hours delayed T<span class="Sub">max</span> (1.67 hours during fasted versus 3.00 hours during fed) under the fed condition compared to the fasted condition. Based on the food effect evaluation on the indomethacin IR capsules, the effect of food on indomethacin pharmacokinetics is comparable between TIVORBEX capsules and indomethacin IR capsules.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Italics">Distribution</span></p>
<p>Indomethacin is highly bound to protein in plasma (about 99%) over the expected range of therapeutic plasma concentrations. Indomethacin crosses the blood-brain barrier and the placenta, and appears in breast milk.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.3"></a><p></p>
<p class="First"><span class="Italics">Metabolism</span></p>
<p>Indomethacin exists in the plasma as the parent drug and its desmethyl, desbenzoyl, and desmethyldesbenzoyl metabolites, all in the unconjugated form. Appreciable formation of glucuronide conjugates of each metabolite and of indomethacin are formed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.4"></a><p></p>
<p class="First"><span class="Italics">Excretion</span></p>
<p>Indomethacin is eliminated via metabolism and subsequent renal and biliary excretion. Indomethacin undergoes appreciable enterohepatic circulation. About 60% of an oral dose is recovered in urine as drug and metabolites (26% as indomethacin and its glucuronide), and 33% is recovered in feces (1.5% as indomethacin). The mean half-life of indomethacin from TIVORBEX capsules 40 mg is 7.6 hours and is comparable to indomethacin IR capsules 50 mg (7.2 hours).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.5"></a><p></p>
<p class="First"><span class="Italics">Special Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.5.1"></a><p></p>
<p class="First"><span class="Italics">Pediatric:</span> The pharmacokinetics of TIVORBEX has not been investigated in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.5.2"></a><p></p>
<p class="First"><span class="Italics">Race:</span> Pharmacokinetic differences due to race have not been identified.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.5.3"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> The pharmacokinetics of TIVORBEX has not been investigated in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.5.4"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> The pharmacokinetics of TIVORBEX has not been investigated in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [see <span class="Italics"><a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.1"></a><p></p>
<p class="First"><span class="Underline">Carcinogenesis</span>: In an 81-week chronic oral toxicity study in the rat at doses up to 1 mg/kg/day (0.08 times the MRHD on a mg/m<span class="Sup">2</span> basis), indomethacin had no tumorigenic effect. Indomethacin produced no neoplastic or hyperplastic changes related to treatment in carcinogenic studies in the rat (dosing period 73 to 110 weeks) and the mouse (dosing period 62 to 88 weeks) at doses up to 1.5 mg/kg/day (0.06 times [mice] and 0.12 times [rats] the MRHD on a mg/m<span class="Sup">2</span> basis, respectively).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.2"></a><p></p>
<p class="First"><span class="Underline">Mutagenesis:</span> Indomethacin did not have any mutagenic effect in in vitro bacterial tests and a series of in vivo tests including the host-mediated assay, sex-linked recessive lethals in Drosophila, and the micronucleus test in mice.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.3"></a><p></p>
<p class="First"><span class="Underline">Impairment of Fertility</span>: Indomethacin at dosage levels up to 0.5 mg/kg/day had no effect on fertility in mice in a two generation reproduction study (0.02 times the MRHD on a mg/m<span class="Sup">2 </span>basis) or a two litter reproduction study in rats (0.04 times the MRHD on a mg/m<span class="Sup">2</span> basis).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The efficacy of TIVORBEX for the treatment of <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> was demonstrated in two multicenter, randomized, double-blind, placebo-controlled, parallel arm studies comparing TIVORBEX 20 mg three times daily, 40 mg twice daily, 40 mg three times daily, and placebo in patients with <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> following bunionectomy (Study 1 and Study 2). The two studies enrolled a total of 835 patients with a mean age of 40 years (range 18 to 68 years) a minimal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity rating of at least 40 mm on a 100-mm visual analog scale (VAS) during the 9-hour period after discontinuation of the anesthetic block following bunionectomy surgery. Patients were randomized equally across the treatment groups.</p>
<p>The mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity measured by VAS at baseline for all treatment groups in both studies ranged from 71 to 74 mm. One tablet of hydrocodone/acetaminophen 10 mg/325 mg was permitted every 4 to 6 hours as rescue medication. There was a greater use of concomitant opioid rescue medication in placebo-treated patients than in TIVORBEX-treated patients. In Study 1, 89% of patients in the TIVORBEX 20 mg three times daily group, 90% of the patients in the TIVORBEX 40 mg twice daily group, 82% in the TIVORBEX 40 mg three times daily group, and 97% of patients in the placebo group took rescue medication for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> management during the study. In Study 2, 87% of patients in the TIVORBEX 20 mg three times daily group, 76% of the patients in the TIVORBEX 40 mg twice daily group, 80% in the TIVORBEX 40 mg three times daily group, and 89% of patients in the placebo group took rescue medication for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> management during the study.</p>
<p>The average <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensities over time are depicted for the treatment groups in <a href="#Fig1">Figure 1</a> for Study 1 and <a href="#Fig2">Figure 2</a> for Study 2. In both studies, TIVORBEX Capsules 20 mg three times daily, 40 mg twice daily and 40 mg three times daily, demonstrated efficacy in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity reduction compared with placebo, as measured by the sum of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity difference over 0 to 48 hours after the first dose.</p>
<p><span class="Bold">Figure 1         Average <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Intensity Over 48 Hours for TIVORBEX and Placebo Groups – Study 1</span></p>
<p><a name="Fig1"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=04ca474c-798e-43dd-be7a-1b36720e6a3d&amp;name=tivorbex-03.jpg"></p>
<p><span class="Bold">Figure 2         Average <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Intensity Over 48 Hours for TIVORBEX and Placebo Groups – Study 2</span></p>
<p><a name="Fig2"></a><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=04ca474c-798e-43dd-be7a-1b36720e6a3d&amp;name=tivorbex-02.jpg"></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">TIVORBEX (indomethacin) are supplied as:</p>
<ul class="Disc">
<li>20 mg, NDC (42211-201-23), Bottles of 30 capsules</li>
<li>20 mg, NDC (42211-201-29), Bottles of 90 capsules</li>
</ul>
<ul class="Disc">
<li>40 mg, NDC (42211-202-23), Bottles of 30 capsules</li>
<li>40 mg, NDC (42211-202-29), Bottles of 90 capsules</li>
</ul>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">Storage</span></p>
<p>Store at 25ºC (77ºF); excursions permitted to 15ºC-30ºC (59ºF-86ºF). [see USP Controlled Room Temperature].</p>
<p>Store in the original container and keep the bottle tightly closed to protect from moisture and light. Dispense in a tight container if package is subdivided.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Bold">See FDA-approved patient labeling (<a href="#mg">Medication Guide</a>). Patients should be informed of the following information before initiating therapy with an NSAID and periodically during the course of ongoing therapy. Patients should also be encouraged to read the NSAID Medication Guide that accompanies each prescription dispensed. </span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1	Cardiovascular Effects</h2>
<p class="First">NSAIDs, including TIVORBEX, may cause serious CV side effects, such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious CV events can occur without warning symptoms, advise patients to be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, slurring of speech, and to ask for medical advice when observing any indicative sign or symptoms. Inform patients of the importance of this follow-up [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.2"></a><a name="section-15.2"></a><p></p>
<h2>17.2	Gastrointestinal Effects</h2>
<p class="First">NSAIDs, including TIVORBEX, can cause GI <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> and, rarely, serious GI side effects, such as <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, advise patients to be alert for the signs and symptoms of ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and to ask for medical advice when observing any indicative sign or symptoms including <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, and <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>. Inform patients of the importance of this follow-up [<span class="Italics">see <a href="#S5.2">Warnings and Precautions (5.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.3"></a><a name="section-15.3"></a><p></p>
<h2>17.3	Adverse <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First">NSAIDs, like TIVORBEX, can cause serious skin side effects such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> (SJS), and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), which may result in hospitalizations and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> may occur without warning, advise patients to be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> and <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or other signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> such as <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and to ask for medical advice when observing any indicative signs or symptoms. Advise patients to stop the drug immediately if they develop any type of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and contact their physicians as soon as possible [<span class="Italics">see <a href="#S5.9">Warnings and Precautions (5.9)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.4"></a><a name="section-15.4"></a><p></p>
<h2>17.4	<span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></h2>
<p class="First">Advise patients to promptly report to their physicians signs or symptoms of unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> during treatment with TIVORBEX [<span class="Italics">see <a href="#S5.5">Warnings and Precautions (5.5)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.5"></a><a name="section-15.5"></a><p></p>
<h2>17.5	Hepatotoxicity</h2>
<p class="First">Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, and "flu-like" symptoms). If these occur, instruct patients to stop therapy and seek immediate medical therapy [<span class="Italics">see <a href="#S5.3">Warnings and Precautions (5.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.6"></a><a name="section-15.6"></a><p></p>
<h2>17.6	<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span></h2>
<p class="First">Inform patients of the signs of an <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat). Instruct patients to seek immediate emergency help if these occur [<span class="Italics">see <a href="#S5.7">Warnings and Precautions (5.7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.7"></a><a name="section-15.7"></a><p></p>
<h2>17.7	Fetal Toxicity</h2>
<p class="First">Inform pregnant women to avoid use of TIVORBEX and other NSAIDs starting at 30 weeks gestation, <span class="Italics">[see <a href="#S5.10">Warnings and Precautions (5.10)</a> and <a href="#S8.1">Use in Specific Populations (8.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First"><span class="Bold">Manufactured (under license from iCeutica Pty Ltd.) for and Distributed by: </span><br>Iroko Pharmaceuticals, LLC<br>One Kew Place<br>150 Rouse Boulevard<br>Philadelphia, PA  19112</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="mg"></a><a name="section-17"></a><p></p>
<h1>Medication Guide for Nonsteroidal Anti-inflammatory Drugs (NSAIDs)</h1>
<p class="First">(See the end of this Medication Guide for a list of prescription NSAID medicines.)</p>
<p><a name="important"></a><span class="Bold">What is the most important information I should know about medicines called Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<p><span class="Bold">NSAID medicines may increase the chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span>.  This chance increases:</p>
<ul class="Disc">
<li>with longer use of NSAID medicines</li>
<li>in people who have heart disease</li>
</ul>
<p><span class="Bold">NSAID medicines should never be used right before or after a heart surgery called a "coronary artery bypass graft (CABG)."</span></p>
<p><span class="Bold">NSAID medicines can cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the stomach and intestines at any time during treatment.  <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>:</span></p>
<ul class="Disc">
<li>can happen without warning symptoms</li>
<li>may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></li>
</ul>
<p><span class="Bold">The chance of a person getting an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> increases with:</span></p>
<ul class="Disc">
<li>taking medicines called "corticosteroids" and "anticoagulants"</li>
<li>longer use</li>
<li>smoking</li>
<li>drinking alcohol</li>
<li>older age</li>
<li>having poor health</li>
</ul>
<p><span class="Bold">NSAID medicines should only be used:</span></p>
<ul class="Disc">
<li>exactly as prescribed</li>
<li>at the lowest dose possible for your treatment</li>
<li>for the shortest time needed</li>
</ul>
<p><span class="Bold">What are Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<p>NSAID medicines are used to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and heat (<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>) from medical conditions such as:</p>
<ul class="Disc">
<li>different types of <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span></li>
<li><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">menstrual cramps</span> and other types of short-term <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
</ul>
<p><span class="Bold">Who should not take a Nonsteroidal Anti-Inflammatory Drug (NSAID)?</span></p>
<p><span class="Bold">Do not take an NSAID medicine:</span></p>
<ul class="Disc">
<li>if you had an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, or other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> with aspirin or any other NSAID medicine</li>
<li>for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> right before or after heart bypass surgery</li>
</ul>
<p><span class="Bold">Tell your healthcare provider:</span></p>
<ul class="Disc">
<li>about all of your medical conditions.</li>
<li>about all of the medicines you take.  NSAIDs and some other medicines can interact with each other and cause serious side effects.  <span class="Bold">Keep a list of your medicines to show to your healthcare provider and pharmacist.</span>
</li>
<li>if you are pregnant. <span class="Bold">NSAID medicines should not be used by pregnant women late in their pregnancy.</span>
</li>
<li>if you are breastfeeding, <span class="Bold">talk to your doctor.</span>
</li>
</ul>
<p><span class="Bold">What are the possible side effects of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<table width="75%">
<col align="left" valign="top" width="60%">
<col align="left" valign="top" width="40%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left" valign="middle">Serious side  effects include:</th>
<th class="Rrule" align="left">Other side  effects include:</th>
</tr></thead>
<tbody><tr class="First Last">
<td class="Lrule Rrule" align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></li>
<li><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
<li>high blood pressure</li>
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> from body <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>)</li>
<li>kidney problems including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span></li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestine</li>
<li>low red blood cells (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>)</li>
<li>life-threatening <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span></li>
<li>life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></li>
<li>liver problems including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span></li>
<li><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks in people who have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></li>
</ul></td>
<td class="Rrule" align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>gas</li>
<li><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
</ul></td>
</tr></tbody>
</table>
<p><span class="Bold">Get emergency help right away if you have any of the following symptoms: </span></p>
<table class="Noautorules" width="75%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing</li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in one part or side of your body</li>
</ul></td>
<td align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat </li>
</ul></td>
</tr></tbody>
</table>
<p><span class="Bold">Stop your NSAID medicine and call your healthcare provider right away if you have any of the following symptoms:</span></p>
<table class="Noautorules" width="75%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li>more tired or weaker than usual</li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
<li>your skin or eyes look yellow</li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li>flu-like symptoms</li>
</ul></td>
<td align="left"><ul class="Disc">
<li>vomit blood</li>
<li>there is blood in your bowel movement or it is black and sticky like tar</li>
<li>unusual <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the arms and legs, hands and feet</li>
</ul></td>
</tr></tbody>
</table>
<p>These are not all the side effects with NSAID medicines.  Talk to your healthcare provider or pharmacist for more information about NSAID medicines.</p>
<p>Call your doctor for medical advice about side effects.  You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">Other information about Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)</span></p>
<ul class="Disc">
<li>Aspirin is an NSAID medicine but it does not increase the chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>.  Aspirin can cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the brain, stomach, and intestines.  Aspirin can also cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestines.</li>
<li>Some of these NSAID medicines are sold in lower doses without a prescription (over-the­ counter).  Talk to your healthcare provider before using over-the-counter NSAIDs for more than 10 days.</li>
</ul>
<table width="75%">
<caption><span>NSAID medicines requiring a prescription</span></caption>
<col align="left" valign="middle" width="20%">
<col align="left" valign="middle" width="80%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Generic Name</th>
<th class="Rrule" align="left">Tradename</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Vicoprofen contains the same dose of ibuprofen as over-the-counter (OTC) NSAIDs, and is usually used for less than 10 days to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.  The OTC NSAID label warns that long term continuous use may increase the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Celecoxib</td>
<td class="Rrule" align="left">Celebrex<span class="Sup">®</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Diclofenac</td>
<td class="Rrule" align="left">Flector<span class="Sup">®</span>, Cataflam<span class="Sup">®</span>, Voltaren<span class="Sup">®</span>, Arthrotec<span class="Sup">®</span> (combined with misoprostol), PENNSAID<span class="Sup">®</span>, Zorvolex<span class="Sup">®</span>, Cambia™, Voltaren<span class="Sup">®</span> gel, Zipsor<span class="Sup">®</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Diflunisal</td>
<td class="Rrule" align="left">Dolobid<span class="Sup">®</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Etodolac</td>
<td class="Rrule" align="left">Lodine<span class="Sup">®</span>, Lodine XL<span class="Sup">®</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Fenoprofen</td>
<td class="Rrule" align="left">Nalfon<span class="Sup">®</span>, Nalfon<span class="Sup">®</span> 200</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Flurbiprofen</td>
<td class="Rrule" align="left">Ansaid<span class="Sup">®</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ibuprofen</td>
<td class="Rrule" align="left">Motrin<span class="Sup">®</span>, Tab-Profen<span class="Sup">®</span>, <a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>Vicoprofen<span class="Sup">®</span> (combined with hydrocodone), Combunox™ (combined with oxycodone), Duexis<span class="Sup">®</span> (combined with famotidine)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Indomethacin</td>
<td class="Rrule" align="left">Indocin<span class="Sup">®</span>, Indocin SR<span class="Sup">®</span>, Indo-Lemmon™, Indomethagan™, Tivorbex™</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ketoprofen</td>
<td class="Rrule" align="left">Oruvail<span class="Sup">®</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ketorolac</td>
<td class="Rrule" align="left">Toradol<span class="Sup">®</span>, SPRIX<span class="Sup">®</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Mefenamic Acid</td>
<td class="Rrule" align="left">Ponstel<span class="Sup">®</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Meloxicam</td>
<td class="Rrule" align="left">Mobic<span class="Sup">®</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Nabumetone</td>
<td class="Rrule" align="left">Relafen<span class="Sup">®</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Naproxen</td>
<td class="Rrule" align="left">Naprosyn<span class="Sup">®</span>, Anaprox<span class="Sup">®</span>, Anaprox<span class="Sup">®</span> DS, EC-Naprosyn<span class="Sup">®</span>, Naprelan<span class="Sup">®</span>, Naprapac<span class="Sup">®</span> (copackaged with lansoprazole), Treximet<span class="Sup">®</span> (combined with sumatriptan succinate) and Vimovo<span class="Sup">®</span> (combined with esomeprazole magnesium)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Oxaprozin</td>
<td class="Rrule" align="left">Daypro<span class="Sup">®</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Piroxicam</td>
<td class="Rrule" align="left">Feldene<span class="Sup">®</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Sulindac</td>
<td class="Rrule" align="left">Clinoril<span class="Sup">®</span>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Tolmetin</td>
<td class="Rrule" align="left">Tolectin<span class="Sup">®</span>, Tolectin DS<span class="Sup">®</span>, Tolectin<span class="Sup">®</span> 600</td>
</tr>
</tbody>
</table>
<p>The brands listed are the trademarks or registered marks of their respective owners.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p><span class="Bold">Manufactured (under license from iCeutica Pty Ltd) for and Distributed by:</span><br>Iroko Pharmaceuticals, LLC<br>One Kew Place<br>150 Rouse Boulevard<br>Philadelphia, PA  19112</p>
<p>Issued: April 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 20 mg Capsule Bottle Label</h1>
<p class="First">N 42211-201-29</p>
<p><span class="Bold Italics">Tivorbex</span>™<br><span class="Bold">(indomethacin) capsules</span></p>
<p><span class="Bold">20 mg<br>per capsule</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">90 Capsules</span></p>
<p>Distributed by <span class="Bold">IROKO</span><span class="Sup">®</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 20 mg Capsule Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=04ca474c-798e-43dd-be7a-1b36720e6a3d&amp;name=tivorbex-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 40 mg Capsule Bottle Label</h1>
<p class="First">N 42211-202-29</p>
<p><span class="Bold Italics">Tivorbex</span>™<br><span class="Bold">(indomethacin) capsules</span></p>
<p><span class="Bold">40 mg<br>per capsule</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">90 Capsules</span></p>
<p>Distributed by <span class="Bold">IROKO</span><span class="Sup">®</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 40 mg Capsule Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=04ca474c-798e-43dd-be7a-1b36720e6a3d&amp;name=tivorbex-05.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TIVORBEX 		
					</strong><br><span class="contentTableReg">indomethacin capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42211-202</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>indomethacin</strong> (indomethacin) </td>
<td class="formItem">indomethacin</td>
<td class="formItem">40 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STEARYL FUMARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (dark blue body and blue cap) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">IP;202;40;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42211-202-29</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:42211-202-23</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:42211-202-42</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">2  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:42211-202-43</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">3  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204768</td>
<td class="formItem">07/06/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TIVORBEX 		
					</strong><br><span class="contentTableReg">indomethacin capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42211-201</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>indomethacin</strong> (indomethacin) </td>
<td class="formItem">indomethacin</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STEARYL FUMARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (dark blue body and light blue cap) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">IP;201;20;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42211-201-29</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:42211-201-23</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:42211-201-43</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">3  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:42211-201-00</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204768</td>
<td class="formItem">07/06/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Iroko Pharmaceuticals, LLC
							(796831217)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Catalent CTS, LLC</td>
<td class="formItem"></td>
<td class="formItem">962674474</td>
<td class="formItem">MANUFACTURE(42211-202, 42211-201)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a4768dbb-09d4-4f01-b19d-56aa6ef63690</div>
<div>Set id: 04ca474c-798e-43dd-be7a-1b36720e6a3d</div>
<div>Version: 3</div>
<div>Effective Time: 20150604</div>
</div>
</div> <div class="DistributorName">Iroko Pharmaceuticals, LLC</div></p>
</body></html>
